Melissa K Accordino1, Jason D Wright1, Donna Buono1, Alfred I Neugut1, Dawn L Hershman2. 1. Columbia University College of Physicians and Surgeons; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons; and Mailman School of Public Health, Columbia University, New York, NY. 2. Columbia University College of Physicians and Surgeons; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons; and Mailman School of Public Health, Columbia University, New York, NY dlh23@columbia.edu.
Abstract
PURPOSE: Image-guided transthoracic needle biopsy (IGTTNB) is an important tool in the diagnosis of patients with cancer. Common complications include pneumothorax and chest tube placement, with rates ranging from 6% to 57%. We performed a population-based study to determine patterns of use, complications, and costs associated with IGTTNB. METHODS: The Premier Perspective database was used to identify patients with cancer with ≥ one claim for IGTTNB from 2006 to 2012. Patients were stratified on the basis of inpatient versus outpatient setting. Pneumothorax was defined by a new claim within 1 month of IGTTNB; hospitalization and chest tube placement rates were analyzed. Multivariable analysis was used to identify factors associated with pneumothorax. RESULTS: We Identified 79,518 patients with cancer who underwent IGTTNB: 42,955 (54.0%) outpatients and 36,563 (46.0%) inpatients. Of patients who underwent outpatient IGTTNB, 5,261 (12.2%) developed a pneumothorax. Of those, 1,006 (19.1%, 2.3% of total) were hospitalized, and 180 (3.4%, 0.42% of total) required chest tubes. Pneumothorax after outpatient IGTTNB was associated with number of comorbidities, rural site, hospital bed size of more than 600, and biopsy of parenchymal as opposed to pleural lesions. Of patients who underwent inpatient IGTTNB, 7,830 (21.4%) developed a pneumothorax, and 2,894 (36.0%, 7.9% of total) required chest tube. Over time, total IGTTNB volume increased by 40.6%, and mean outpatient cost per procedure increased by 24.4%. CONCLUSION: While pneumothorax was frequent in outpatients, rates of hospitalization and chest tube placement were low. As screening for lung cancer increases, we anticipate an increased need for IGTNBB. Patients can be reassured by the low rate of serious complications.
PURPOSE: Image-guided transthoracic needle biopsy (IGTTNB) is an important tool in the diagnosis of patients with cancer. Common complications include pneumothorax and chest tube placement, with rates ranging from 6% to 57%. We performed a population-based study to determine patterns of use, complications, and costs associated with IGTTNB. METHODS: The Premier Perspective database was used to identify patients with cancer with ≥ one claim for IGTTNB from 2006 to 2012. Patients were stratified on the basis of inpatient versus outpatient setting. Pneumothorax was defined by a new claim within 1 month of IGTTNB; hospitalization and chest tube placement rates were analyzed. Multivariable analysis was used to identify factors associated with pneumothorax. RESULTS: We Identified 79,518 patients with cancer who underwent IGTTNB: 42,955 (54.0%) outpatients and 36,563 (46.0%) inpatients. Of patients who underwent outpatient IGTTNB, 5,261 (12.2%) developed a pneumothorax. Of those, 1,006 (19.1%, 2.3% of total) were hospitalized, and 180 (3.4%, 0.42% of total) required chest tubes. Pneumothorax after outpatient IGTTNB was associated with number of comorbidities, rural site, hospital bed size of more than 600, and biopsy of parenchymal as opposed to pleural lesions. Of patients who underwent inpatient IGTTNB, 7,830 (21.4%) developed a pneumothorax, and 2,894 (36.0%, 7.9% of total) required chest tube. Over time, total IGTTNB volume increased by 40.6%, and mean outpatient cost per procedure increased by 24.4%. CONCLUSION: While pneumothorax was frequent in outpatients, rates of hospitalization and chest tube placement were low. As screening for lung cancer increases, we anticipate an increased need for IGTNBB. Patients can be reassured by the low rate of serious complications.
Authors: Hossein Masoomi; Celeste Y Kang; Anne Chen; Steven Mills; Matthew O Dolich; Joseph C Carmichael; Michael J Stamos Journal: J Am Coll Surg Date: 2012-05-27 Impact factor: 6.113
Authors: D L Hershman; C A Richards; K Kalinsky; E T Wilde; Y S Lu; J A Ascherman; A I Neugut; J D Wright Journal: Breast Cancer Res Treat Date: 2012-09-29 Impact factor: 4.872
Authors: Patricia R Geraghty; Stephen T Kee; Gillian McFarlane; Mahmood K Razavi; Daniel Y Sze; Michael D Dake Journal: Radiology Date: 2003-11 Impact factor: 11.105
Authors: Abraham Markin; Elizabeth B Habermann; Christopher J Chow; Yanrong Zhu; Selwyn M Vickers; Waddah B Al-Refaie Journal: Am J Surg Date: 2012-08-17 Impact factor: 2.565
Authors: Jason D Wright; Alfred I Neugut; Cande V Ananth; Sharyn N Lewin; Elizabeth T Wilde; Yu-Shiang Lu; Thomas J Herzog; Dawn L Hershman Journal: JAMA Intern Med Date: 2013-04-08 Impact factor: 21.873
Authors: Melissa K Accordino; Jason D Wright; Sowmya Vasan; Alfred I Neugut; Grace C Hillyer; Dawn L Hershman Journal: Cancer Invest Date: 2017-02-06 Impact factor: 2.176
Authors: Zhu Cui; Jason D Wright; Melissa K Accordino; Donna Buono; Alfred I Neugut; Jim C Hu; Dawn L Hershman Journal: Cancer Invest Date: 2016-04-11 Impact factor: 2.176
Authors: Richard B Lanman; Stefanie A Mortimer; Oliver A Zill; Dragan Sebisanovic; Rene Lopez; Sibel Blau; Eric A Collisson; Stephen G Divers; Dave S B Hoon; E Scott Kopetz; Jeeyun Lee; Petros G Nikolinakos; Arthur M Baca; Bahram G Kermani; Helmy Eltoukhy; AmirAli Talasaz Journal: PLoS One Date: 2015-10-16 Impact factor: 3.240
Authors: Hedvig Hricak; May Abdel-Wahab; Rifat Atun; Miriam Mikhail Lette; Diana Paez; James A Brink; Lluís Donoso-Bach; Guy Frija; Monika Hierath; Ola Holmberg; Pek-Lan Khong; Jason S Lewis; Geraldine McGinty; Wim J G Oyen; Lawrence N Shulman; Zachary J Ward; Andrew M Scott Journal: Lancet Oncol Date: 2021-03-04 Impact factor: 41.316